News for AGN's proof of concept study evaluating its IP Fibr The pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN.c $AGNPF) recently announced that it has met the co-primary endpoint in its Phase 2 proof of concept study evaluating its drug, Ifenprodil, for the potential treatment of idiopathic pulmonary fibrosis & chronic cough.
65% in the study of patients had statistically significant stable or IFV (aka the amount of air that can be forcibly exhaled) capacity over the 12-week treatment period.
Additionally, 30% of subjects achieved a 50% reduction in the average number of coughs per hour over 24 hours from baseline to week 12.
Personally, I think these results are pretty promising and definitely worth looking into if you are interested in the biotech sector: https://lifesciencesbc.ca/members/algernon-pharmaceuticals-hits-co-primary-endpoint-in-its-phase-2-study-of-ifenprodil-for-idiopathic-pulmonary-fibrosis-and-chronic-cough/
Today AGN closed @ $3.07, MC $5.142M